Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 533

1.

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH.

Int J Mol Sci. 2016 Apr 15;17(4). pii: E570. doi: 10.3390/ijms17040570.

2.

Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation.

Katagiri S, Gotoh M, Tone K, Akahane D, Ito Y, Ohyashiki K, Makimura K.

Int J Hematol. 2016 May;103(5):592-5. doi: 10.1007/s12185-016-1953-y. Epub 2016 Feb 15.

PMID:
26879198
3.

Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.

Ohyashiki JH, Umezu T, Ohyashiki K.

Curr Opin Hematol. 2016 May;23(3):268-73. doi: 10.1097/MOH.0000000000000235.

PMID:
26866730
4.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.

Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.

Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.

PMID:
26355708
5.

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.

Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K.

J Hematol Oncol. 2015 Aug 4;8:97. doi: 10.1186/s13045-015-0190-9.

6.

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Sep;90(9):819-24. doi: 10.1002/ajh.24096.

PMID:
26103598
7.

Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.

Imanishi S, Takahashi R, Ohsuga M, Ohyashiki K, Ohyashiki JH.

Ann Hematol. 2015 Sep;94(9):1601-2. doi: 10.1007/s00277-015-2417-9. Epub 2015 Jun 6. No abstract available.

PMID:
26044890
9.

[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].

Katagiri S, Tauchi T, Umezu T, Saito Y, Suguro T, Asano M, Yoshizawa S, Kitahara T, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki JH, Ohyashiki K.

Rinsho Ketsueki. 2015 Feb;56(2):216-9. doi: 10.11406/rinketsu.56.216. Japanese.

PMID:
25765803
10.

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2.

11.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

12.

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood. 2014 Dec 11;124(25):3748-57. doi: 10.1182/blood-2014-05-576116. Epub 2014 Oct 15.

13.

Diffuse large B-cell lymphoma resembling a metastatic liver tumour.

Saitoh Y, Gotoh M, Katagiri S, Ohyashiki K.

Br J Haematol. 2015 Jan;168(1):1. doi: 10.1111/bjh.13163. Epub 2014 Oct 14. No abstract available.

PMID:
25312576
14.

Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.

Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; Japan Febrile Neutropenia Study Group.

J Infect Chemother. 2015 Jan;21(1):16-22. doi: 10.1016/j.jiac.2014.08.026. Epub 2014 Sep 17.

PMID:
25239059
15.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812. eCollection 2014.

16.

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K.

Oncoimmunology. 2014 May 14;3:e28861. eCollection 2014.

17.

Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.

Gotoh M, Yoshizawa S, Katagiri S, Suguro T, Asano M, Kitahara T, Akahane D, Okabe S, Tauchi T, Ito Y, Ohyashiki K.

Transpl Infect Dis. 2014 Jun;16(3):440-9. doi: 10.1111/tid.12229. Epub 2014 May 9.

PMID:
24810656
18.

[Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia].

Katagiri S, Yoshizawa S, Gotoh M, Nakamura I, Ohyashiki K.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):734-7. Japanese. No abstract available.

PMID:
24796145
19.

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.

J Hematol Oncol. 2014 Apr 28;7:37. doi: 10.1186/1756-8722-7-37.

20.

A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Gotoh M, Yoshizawa S, Katagiri S, Suguro T, Asano M, Kitahara T, Akahane D, Okabe S, Tauchi T, Ito Y, Ohyashiki K.

Bone Marrow Transplant. 2014 Jul;49(7):955-60. doi: 10.1038/bmt.2014.66. Epub 2014 Apr 14.

PMID:
24732960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk